Chelsea Therapeutics soared 1.47, or 61%, to 3.88, after the biopharmaceutical company said a Food and Drug Administration committee recommended the approval of its treatment for neurogenic orthostatic hypotension.

WSJ: S&P 500 Notches Highest Close Since June 2008